Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway
- 1 May 2012
- journal article
- research article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 125 (2), 458-469
- https://doi.org/10.1016/j.ygyno.2012.01.009
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- PIK3R1 (p85α) Is Somatically Mutated at High Frequency in Primary Endometrial CancerCancer Research, 2011
- Metformin Decreases the Dose of Chemotherapy for Prolonging Tumor Remission in Mouse Xenografts Involving Multiple Cancer Cell TypesCancer Research, 2011
- A Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial CarcinomasClinical Cancer Research, 2011
- PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis InhibitorsMolecular Cancer Therapeutics, 2011
- Metformin: A Therapeutic Opportunity in Breast CancerClinical Cancer Research, 2010
- Metformin is a potent inhibitor of endometrial cancer cell proliferation—implications for a novel treatment strategyGynecologic Oncology, 2010
- Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong RemissionCancer Research, 2009
- Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosisInternational Journal of Cancer, 2009
- Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast CancerJournal of Clinical Oncology, 2009
- New Users of Metformin Are at Low Risk of Incident CancerDiabetes Care, 2009